See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $121B | 10.7x | 54.4x | |
| $10.8B | 3.7x | 15.8x | |
| $4.3B | 12.6x | 34.5x | |
| $2.5B | 743.5x | -87.1x | |
| $2.3B | 8.9x | 21.9x | |
| $2.3B | 4.1x | 38.5x | |
| $2.0B | 8.1x | 34.5x | |
| $1.6B | 36.3x | -3.6x | |
| $1.4B | 90.6x | -30.0x | |
| $1.2B | 5.0x | 29.5x | |
| $1.1B | 496.2x | -50.2x | |
| $1.0B | 15.9x | -2.4x | |
| $899M | 2.5x | 11.6x | |
| $726M | 3.7x | 32.0x | |
| $565M | 1.2x | 11.7x | |
| $402M | 13.0x | -2.4x | |
| $397M | n/a | n/a | |
| $390M | 6.7x | 33.0x | |
| $382M | 12.7x | 26.1x | |
| $364M | 9.8x | -13.1x | |
| $357M | 6.5x | -0.7x | |
| $328M | 24.7x | -1.4x | |
| $302M | n/a | n/a | |
| $232M | 91.3x | n/a | |
| $207M | 0.6x | n/a | |
| $178M | 36.9x | -51.7x | |
| $170M | 6.4x | 13.3x | |
| $169M | 1.4x | 12.4x | |
| $164M | n/a | n/a | |
| $106M | 3.9x | -8.2x | |
| $106M | n/a | n/a | |
| $92.0M | n/a | n/a | |
| $79.4M | 1.6x | 48.8x | |
| $69.6M | n/a | -5.2x | |
| $50.7M | 30.3x | n/a | |
| $48.3M | 4.8x | -2.2x | |
| $41.5M | n/a | n/a | |
| $36.2M | n/a | n/a | |
| $27.6M | n/a | n/a | |
| $21.1M | 27.6x | n/a | |
| $21.1M | n/a | n/a | |
| $18.9M | 4.9x | n/a | |
| $8.2M | 1.4x | n/a | |
| $4.1M | 1.7x | n/a | |
| -$250M | -4.3x | 1.2x | |
| -$253M | -4757.5x | 1.4x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine